Journal of clinical periodontology · 2025
The Use of a Resorbable Membrane as an Adjunct to a Xenogeneic Bone Replacement Graft in the Reconstructive Surgical Therapy of Peri-Implantitis: 3-Year Results of a Randomised Clinical Trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dionigi Carlotta, Regidor Erik, Trullenque-Eriksson Anna, Derks Jan, Sanz Mariano, Ortiz-Vigón Alberto
Аннотация
AIM: To evaluate the effect of the adjunctive use of a resorbable collagen membrane in the reconstructive surgical therapy of peri-implantitis.
MATERIAL AND METHODS: Forty-three patients (43 implants) diagnosed with peri-implantitis underwent surgical treatment using a reconstructive approach, which included a bone substitute material with (test) or without (control) a resorbable collagen membrane. Supportive peri-implant treatment was administered biannually during the 3-year follow-up period. Clinical outcomes, such as probing pocket depth (PPD), bleeding on probing (BOP), suppuration on probing (SOP), marginal mucosal level (REC) and keratinised mucosa width (KM), were recorded at baseline, as well as at 6, 12 and 36 months. Radiographic marginal bone levels (MBLs) and patient-reported outcomes (PROs) were also evaluated. The primary outcome was a composite measure consisting of PPD ≤ 5 mm, absence of BOP/SOP and buccal REC of ≤ 1 mm. A second composite outcome, termed 'disease resolution', was also assessed, defined as PPD ≤ 5 mm, BOP at ≤ 1 site and complete absence of SOP.
RESULTS: Out of the 43 participants, 8 were lost to follow-up, 2 experienced implant loss and 1 was surgically re-treated. At 3 years, the composite outcome was achieved for 25.0% of implants (test: 17.6%; control: 27.8%), while disease resolution was achieved for 31.2% (test: 29.4%; control: 27.8%). Overall, PPD and BOP were reduced by 3.6 ± 3.2 mm and 37.5% ± 42.1%, respectively. Changes in buccal REC and KM were 0.5 ± 1.3 and 1.1 ± 1.5 mm, respectively. An overall bone gain (MBL change) of 1.0 ± 2.2 mm was observed. PROs were favourable. No statistically significant differences were observed between groups.
CONCLUSION: Adding a collagen membrane to a bone substitute material in the surgical treatment of peri-implantitis did not yield any benefits regarding clinical, radiographic or patient-reported outcomes.
TRIAL REGISTRATION: ISRCTN67095066 (https://www.isrctn.com/ISRCTN67095066).
MATERIAL AND METHODS: Forty-three patients (43 implants) diagnosed with peri-implantitis underwent surgical treatment using a reconstructive approach, which included a bone substitute material with (test) or without (control) a resorbable collagen membrane. Supportive peri-implant treatment was administered biannually during the 3-year follow-up period. Clinical outcomes, such as probing pocket depth (PPD), bleeding on probing (BOP), suppuration on probing (SOP), marginal mucosal level (REC) and keratinised mucosa width (KM), were recorded at baseline, as well as at 6, 12 and 36 months. Radiographic marginal bone levels (MBLs) and patient-reported outcomes (PROs) were also evaluated. The primary outcome was a composite measure consisting of PPD ≤ 5 mm, absence of BOP/SOP and buccal REC of ≤ 1 mm. A second composite outcome, termed 'disease resolution', was also assessed, defined as PPD ≤ 5 mm, BOP at ≤ 1 site and complete absence of SOP.
RESULTS: Out of the 43 participants, 8 were lost to follow-up, 2 experienced implant loss and 1 was surgically re-treated. At 3 years, the composite outcome was achieved for 25.0% of implants (test: 17.6%; control: 27.8%), while disease resolution was achieved for 31.2% (test: 29.4%; control: 27.8%). Overall, PPD and BOP were reduced by 3.6 ± 3.2 mm and 37.5% ± 42.1%, respectively. Changes in buccal REC and KM were 0.5 ± 1.3 and 1.1 ± 1.5 mm, respectively. An overall bone gain (MBL change) of 1.0 ± 2.2 mm was observed. PROs were favourable. No statistically significant differences were observed between groups.
CONCLUSION: Adding a collagen membrane to a bone substitute material in the surgical treatment of peri-implantitis did not yield any benefits regarding clinical, radiographic or patient-reported outcomes.
TRIAL REGISTRATION: ISRCTN67095066 (https://www.isrctn.com/ISRCTN67095066).